Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03093116
Recruitment Status : Recruiting
First Posted : March 28, 2017
Last Update Posted : August 12, 2022
Zai Lab (Shanghai) Co., Ltd.
Information provided by (Responsible Party):
Turning Point Therapeutics, Inc.